Gossamer Bio Inc GOSS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if GOSS is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- $0.81
- Day Range
- $0.77–0.85
- 52-Week Range
- $0.45–1.88
- Bid/Ask
- $0.78 / $0.79
- Market Cap
- $176.81 Mil
- Volume/Avg
- 627,226 / 1.4 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 135
- Website
- https://www.gossamerbio.com
Comparables
Valuation
|
Metric
|
GOSS
|
RYTM
|
AVIR
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 2.89 | 13.34 | 0.56 |
Price/Sales | — | 28.39 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
GOSS
RYTM
AVIR
Financial Strength
|
Metric
|
GOSS
|
RYTM
|
AVIR
|
|---|---|---|---|
Quick Ratio | 5.74 | 5.27 | 17.86 |
Current Ratio | 5.94 | 5.58 | 18.24 |
Interest Coverage | −12.46 | −13.26 | — |
Quick Ratio
GOSS
RYTM
AVIR
Profitability
|
Metric
|
GOSS
|
RYTM
|
AVIR
|
|---|---|---|---|
Return on Assets (Normalized) | −52.69% | −46.12% | −15.46% |
Return on Equity (Normalized) | −796.84% | −76.97% | −16.16% |
Return on Invested Capital (Normalized) | −54.51% | −76.40% | −19.92% |
Return on Assets
GOSS
RYTM
AVIR
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Mtykzfjrk | Kxws | $550.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Jvgsrgvpx | Pcpxl | $101.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Phvmqcpqt | Llzkstf | $98.1 Bil | |
MRNA
| Moderna Inc | Rntfwvx | Qkg | $39.1 Bil | |
ARGX
| argenx SE ADR | Xknnphjq | Zbws | $21.7 Bil | |
BNTX
| BioNTech SE ADR | Gbvsfpfs | Xkd | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Vytqpzqj | Mcxzxy | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Ybghgvflm | Jjnrxb | $17.1 Bil | |
RPRX
| Royalty Pharma PLC Class A | Nvnlwwnspc | Pswhkt | $12.5 Bil | |
INCY
| Incyte Corp | Gtbkybqz | Rvkgrfn | $11.9 Bil |